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Abstract 
Objective: Microfluidic technology has the potential to miniaturize and automate complex laboratory procedures. 
The objective of this study was to assess a microfluidic immunoassay device, Simple Plex, which simultaneously 
measured IL-1β, TNF-α, IL-6, and IL-10 in serum samples. This assessment is important to understanding the potentials 
of this microfluidic device as a valuable tool in translational research efforts.
Methods: We studied the operational characteristics of Simple Plex, and compared to other immunoassay systems 
including bead-based (i.e., Bio-Plex® from Bio-Rad) and planar micro-spot based (i.e., Multi-Array from Meso Scale 
Discovery) multiplex assays. We determined imprecisions for each of the Simple Plex assays and evaluated the ability 
of Simple Plex to detect IL-1β, TNF-α, IL-6, and IL-10 in serum samples.
Results: Simple Plex assays required 25 µL serum, and 1.5 h to run 16 samples per cartridge per instrument. Assay 
imprecisions, evaluated by measurement of 6 replicates in duplicate from a serum pool using three different car-
tridges, were less than 10 % for all 4 cytokine protein biomarkers, comparable to the imprecisions of traditional ELISAs. 
The Simple Plex assays were able to detect 32, 95, 97, and 100 % [i.e., percentages of the results within the respective 
analytical measurement ranges (AMRs)] of IL-1β, TNF-α, IL-6, and IL-10, respectively, in 66 serum samples.
Conclusions: Simple Plex is a microfluidic multiplex immunoassay device that offers miniaturized, and automated 
analysis of protein biomarkers. Microfluidic devices such as Simple Plex represent a promising platform to be used in 
translational research to measure protein biomarkers in real clinical samples.
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Background
The technology of microfluidics is one that manipulates 
small volumes of fluid and flow that has the potential to 
miniaturize complex laboratory procedures [1, 2]. Micro-
fluidic technology has been widely used in point-of-care 
(POC) devices for clinical diagnostics (e.g., iSTAT) [3–7]. 
Since these devices generally require small sample vol-
umes there is much interest in applying microfluidic tech-
nology to areas outside of the traditional realms of POC 
diagnostics and into areas in translational research efforts 
such as the quantitative measurement of multiple pro-
tein biomarkers (multiplexing) [8–11]. One of the most 
widely used approaches for quantitative multiplexing of 
proteins is multiplex immunoassay [8]. There are several 
different platforms that are used to perform this type of 
analysis and some examples of this are: bead–based flow 
cytometry (e.g., Bio-Plex® and Luminex®), and planar 
assays containing a defined array of capture microspots 
deposited in the bottom of the well (e.g., Multi-Array 
and Aushon Biosystem) [12]. While the above platforms 
have shown great utility in multiplexing quantitation, 
the microfluidics platform offers several advantages by 
its design. First, microfluidics allows for separate incu-
bation chambers for every analyte; that is, each incuba-
tion chamber is limited to one antibody pair to react with 
its respective analyte. This prevents the potential issue 
of cross-reactivity (i.e., antigen cross-reacting to other 
antibody pairs) [13]; second, the consumption of reagent 
and sample volume is low due to miniaturized design, 
and therefore researchers are able to conserve precious 
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reagents and samples [14]; third, microfluidics provides 
a means for automation where it may be able to automate 
sample preparation, incubation, and detection all on one 
device (or lab-on-a-chip) so that complex lab procedures 
can be minimized [1].
Despite all the potential advantages, multiplex immu-
noassays based on microfluidic technology have yet 
to be generally employed in translational research for 
measurement of protein biomarkers. This is likely due 
to that microfluidics by itself does not offer the sensitiv-
ity and specificity needed for measurement of proteins 
[15]. There has been interest in coupling microfluidics 
with nanotechnology, which would offer novel capture of 
antigens (selectivity) and improved detection (sensitiv-
ity) [16–20]. Recently, ProteinSimple has commercialized 
a microfluidic multiplexed immunoassay platform cou-
pled with glass nanoreactors (GNRs) [21]. The objective 
of this study was to assess Simple Plex for measurement 
of the following protein biomarkers in patient serum 
samples: IL-1β, TNF-α, IL-6, and IL-10. We chose these 
cytokines for several reasons: (a) they are often meas-
ured simultaneously and involved in numerous acute and 
chronic disease conditions as part of balanced act of the 
immune system [22]; and (b) their concentrations can 
span wide dynamic ranges, from very low under non-
pathological conditions to extremely high under acute 
inflammatory conditions, and therefore they can be very 
analytically challenging to measure simultaneously [12]. 
This assessment was key to understanding the potentials 
of this microfluidic multiplexed immunoassay platform 
and was a valuable tool to determine efficacy for transla-
tional research efforts in the quantitative measurement of 
multiple protein biomarkers in real clinical samples.
Methods
Clinical samples
Serum samples were randomly selected from the Endo-
crinology Laboratory at the University of Minnesota 
Medical Center, Fairview. Samples were stored frozen at 
−80  °C. The study protocol was reviewed and approved 
by the University of Minnesota Institutional Review 
Board (IRB).
Multiplex protein biomarker measurement by Simple Plex
Protein biomarkers, IL-1β, TNF-α, IL-6, and IL-10, were 
measured in the serum samples using Simple Plex (Pro-
teinSimple, San Jose, CA) following the manufacturer’ 
instruction. The work flow of the Simple Plex assays is 
that: (a) a test cartridge is primed with samples with each 
sample split into 4 channels (i.e., IL-1β, TNF-α, IL-6, and 
IL-10) to react with their respective antibodies immobi-
lized on glass nanoreactors; (b) after sample incubation, 
circuits in the cartridge are cleaned with wash buffer, 
and biotinylated detection antibody solutions are indi-
vidually pumped into their respective channels to bind 
to protein analyte captured on the GNRs; (c) after incu-
bation, unbound detection antibodies are washed away 
and a detection solution (i.e., streptavidin DyLight 650) 
is flowed into all 4 channels to conjugate with the bioti-
nylated detection antibodies; (d) the detection solution is 
washed away; detection fluorophores (i.e., DyLight 650) 
are excited with a 631  nm laser; and the fluorescence 
signals are read with a charge-coupled device (CCD) 
camera. The signals are used for quantification based on 
master calibrator curves provided by the manufacturer. 
Simple Plex uses 25 µL of serum for measurement of the 
four cytokines. Precisions of the Simple Plex assays were 
evaluated by duplicate measurement of a pooled serum 
sample on three different Simple Plex cartridges. Sixty-
six serum samples were measured using Simple Plex car-
tridges from the same lot on 2 consecutive days.
Comparison of Simple Plex to ELISAs and other multiplex 
immunoassays
We measured IL-1β, TNF-α, IL-6, and IL-10 in these 
66 samples using ELISAs (Bio-Techne, formerly R&D 
systems, Minneapolis, MN) and studied the operation 
characteristics of ELISAs from our own experiments. 
Although we did not measure IL-1β, TNF-α, IL-6, and 
IL-10 in these 66 samples using the Bio-Plex® and Multi-
Array assays, we included the operational characteris-
tics of the BioPlex® and Multi-Array assays, which were 
derived from our previous experiences in using these sys-
tems [23–25], in the comparison to those of the Simple 
Plex and ELISAs.
Results
Operational characteristics of Simple Plex, traditional 
ELISAs, and two other multiplex immunoassay systems 
(i.e., Bio-Plex® and Multi-Array) are listed in Table  1. 
Assay imprecisions were evaluated on 6 replicates of 
duplicate measurements from a pooled serum sample 
on three different cartridges for IL-1β, TNF-α, IL-6, and 
IL-10, which were found to be 6.2, 8.0, 6.2 and 9.1  %, 
respectively. The imprecisions of the Simple Plex assays 
were comparable to those of the traditional ELISAs, 
which were evaluated using replicates of the same serum 
sample pool, to be 9.0, 6.6, 14.5, and 8.3  %, for IL-1β, 
TNF-α, IL-6, and IL-10, respectively. Table  2 shows the 
analytical measurement ranges (AMRs) provided by 
the manufacturer, and the percentages of samples that 
have results within their respective AMRs, which were 
32, 95, 97, and 100 % for IL-1β, TNF-α, IL-6, and IL-10, 
respectively. The Simple Plex assay did not have the AMR 
to measure IL-1β levels in 68  % of the 66 samples; that 
is, 68  % of the samples had IL-1β levels lower than the 
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lower limit of the AMR, which was 0.21 pg/mL (Table 2). 
We also compared concentration values obtained by the 
Simple Plex assays and ELISAs in measurement of IL-1β, 
TNF-α, IL-6, and IL-10 (Fig.  1). Not all 66 samples had 
measurable results by these assays. For IL-1β and IL-6 
assays, the Simple Plex assays used the same antibody 
pairs as the ELISAs, and demonstrated good correlations 
by Deming regression, with R2 of 0.99 and 0.98, for IL-1β 
and IL-6, respectively (Fig. 1a, c). For samples with meas-
urable results by both ELISA and Simple Plex, poor cor-
relations between the Simple Plex assays and the ELISAs 
were observed for TNF-α (n =  34) and IL-10 (n =  20), 
presumably due to different antibodies used by the differ-
ent manufacturers (i.e., ProteinSimple and Bio-Techne) 
in these two assays (Fig. 1b, d).
Discussion
The classical approach for quantitating proteins is gener-
ally based on immunoassays, particularly ELISAs. How-
ever, ELISAs are typically low throughput, require large 
sample volumes, and have a relatively high cost due to 
labor and large amount of reagents consumed (Table 1), 
especially when they are done manually. To circumvent 
some of these issues, multiplex immunoassays have been 
developed, which include planar micro-spot based (e.g., 
multi-array from meso scale discovery) and bead-based 
detections (e.g., Bio-Plex® from Bio-Rad) to increase 
throughput (i.e., multiple analytes vs. single analyte) and 
conserve sample volume [23–25] (Table  1). One signifi-
cant difference between the multiplex immunoassays and 
ELISAs is the fact that, in the planar micro-spot based 
and bead-based multiplex immunoassays, all antibody 
pairs required to measure the proteins of interest need 
to be present in the reagent; whereas in the ELISAs, only 
one antibody pair is present in the reagent. Ideally, anti-
bodies should only bind to their respective antigens, and 
vice versa. However, in reality, antibodies bind to not 
only their respective antigens, but also other molecules 
present in a sample. Therefore, presence of multiple anti-
body pairs increases the possibility of antibodies react-
ing with each others, giving rise to potential off-target 
effects [12]. Microfluidic-based approaches to multi-
plexed immunoassay, such as Simple Plex, is an appealing 
alternative because the design is such that each antibody 
pair is isolated in its own unit and therefore, completely 
eliminates cross talk [13, 21]. More importantly, such 
design would allow each analyte to be optimized (i.e., the 
amount of antibody, and the dilution factor of the sam-
ple, and sample volume) in order to achieve the sensitiv-
ity and AMR needed for a specific application.
Currently, the Simple Plex is more automated than 
either BioPlex® or multi-array assays, whereas the Bio-
Plex® or multi-array assays still require several manual 
steps, such as adding reagents, washing the plates, and 
reading the plates before results can be obtained. For 
the Simple Plex device, users only need to pipet sam-
ples into the cartridge, insert the cartridge into the ana-
lyzer, and hit the “go” button to obtain results. Reagents 
are incorporated within the cartridges, and no calibra-
tors are needed as cartridges are pre-calibrated by the 
manufacturer. Because of this higher level of automa-
tion (i.e., adding reagents, washing and reading plates), 
the total analysis time of Simple Plex assays was found 
to be much shorter than either Bio-Plex® or Multi-Array 
assays (1.5 h versus 4–6 h) (Table 1). However, the Sim-
ple Plex analyzes 16 samples in a cartridge, less than 96 
samples that the Bio-Plex® and Multi-Array assays would 
Table 1 Operational characteristics of the Simple Plex device in comparison with peer immunoassay systems
a Minimal volume needed to perform 4 ELISAs for measurement of IL-1β, TNF-α, IL-6, and IL-10 in singleton
Method ELISA Bio Plex Multi-array Simple Plex
Manufacturer Bio-Techne BioRad Mesoscale discovery ProteinSimple
Number of analytes Single analyte Up to 100 anaytes Up to 12 analytes Up to 8 analytes
Format 96-well plate 96-well plate 96-well plate Cartridge pre-filled with reagents
Detection Absorbance Fluorescence Electrochemiluminescence Fluorescence
Capacity (# samples/run) 96 96 96 16
Assay time 4–6 h/run 4-6 h/run 4-6 h/run 1.5 h/run
Level of automation (low, medium, high) Low Medium Medium High
Volume needed 600 µLa 25 µL 25 µL 25 µL
Table 2 The ability of  the Simple Plex assays to  detect 
IL-1β, TNF-α, IL-6, and IL-10 in real clinical samples
a AMRs of the Simple Plex assays were provided by the manufacturer




IL-1β 0.21–2000 32 68
TNF-α 1.31–5000 95 5
IL-6 0.52–2000 97 3
IL-10 0.21–2000 100 0
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be able to analyze in a 96 well plate. It uses 25 μL sample, 
the same as Bio-Plex® and Multi-Array assays. Therefore, 
in order to offer more advantageous features, the Simple 
Plex device should consider improving its throughput (16 
samples per cartridge) and decreasing required sample 
volume (25 μL).
A frequent constraint inherent to miniaturization and 
microfluidics is the low signal-to-noise ratio and the 
low detectability of the analytical signals [15]. Therefore, 
many publications involving microfluidic methods alone 
do not describe their applications to the analysis of real 
serum samples. The use of nanomaterials in microfluid-
ics is a recent trend to improve sensitivity and selectivity, 
which is crucial in measurement of real clinical samples. 
Nanomaterials have been used in different steps of the 
analytical process of a microfluidic device: preconcentra-
tion, separation, reaction, and detection [15]. Nanomate-
rials offer properties such as large surface area-to-volume 
ratio and relative easy functionalization for preconcen-
tration and separation steps (e.g., by coupling to anti-
bodies or other biomolecules). Also, nanomaterials have 
been used as buffer additives and as stationary phases 
in microchip electrochromatography [26]. Furthermore, 
nanomaterials offer catalytic properties and capability to 
act as electron-transfer mediators to improve analytical 
reaction in microfluidic methods [27]. Last but not least, 
nanomaterials are used in the detection step to improve 
the sensitivity of microfluidic methods [15]. Simple Plex 
assays use GNRs, which are hollow, cylindrical reaction 
chambers composed of fused silica, in improving selec-
tivity and sensitivity in separation and detection steps. 
These porous silica nanoreactors are functionalized to 
offer a highly uniformed, solid phase immobilization of 
detection antibodies on the internal surface of the nano-
reactor. The optical properties of the glass nanoreactors 
are ideally suited for subsequent fluorescent detection 
(i.e., low intrinsic fluorescence) [21].
Our results in applying the Simple Plex methodology to 
real clinical samples, randomly selected from our Endo-
crine Laboratory, showed that the IL-1β assay did not 
have enough sensitivity (i.e., the low limit of the AMR) 
for 68  % of the 66 samples analyzed (Table  2). Future 
assay generations may address this lack of sensitivity 
by designing a micro-fluidic cartridge where splitting 
Fig. 1 Method comparison between the ELISAs and the Simple Plex assays using Deming regression for measurement of IL-1β (a), TNF-α (b), IL-6 
(c), and IL-10 (d)
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the specimen into different volumes so that the volume 
for IL-1β assay will be set optimally for the purpose of 
improving sensitivity. Alternatively, chemiluminescent 
detection, which usually is more sensitive than fluores-
cence detection, may be another way to increase the sen-
sitivity of this device [28].
The Simple Plex device embodies a current trend of 
combining microfluidics with nanotechnology for simul-
taneous measurement of protein biomarkers. Our study 
illustrated the significant advantages of the Simple Plex 
device over traditional multiplex immunoassay systems 
in its miniaturization and automation analysis. Despite 
the limitation in sensitivity for certain analyte (i.e., 
IL-1β), microfluidic devices such as Simple Plex repre-
sent a promising technological platform to be used in 
translational research for simultaneous measurement of 
multiple protein biomarkers in real samples.
Abbreviations
IL-1β: Interleukin-1 beta; IL-6: Interleukin-6; IL-10: Interleukin-10; TNF-α: Tumor 
necrosis factor-α; CV: Coefficients of variation; AMR: Analytical measurement 
range; QC: Quality control.
Authors’ contributions
JC collected the specimens and provided the specimens for the method 
comparison study, and performed data analysis. JS provided valuable com-
ments to the manuscript. NQH and CZ helped design and perform the study. 
DL provided the concept for this study and wrote the manuscript. All authors 
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 November 2015   Accepted: 30 November 2015
References
 1. Whitesides GM. The origins and the future of microfluidics. Nature. 
2006;442:368–73.
 2. Manz A, Graber N, Widmer HÁ. Miniaturized total chemical analysis sys-
tems: a novel concept for chemical sensing. Sensors Actuators B Chem. 
1990;1:244–8.
 3. Sia SK, Kricka LJ. Microfluidics and point-of-care testing. Lab Chip. 
2008;8:1982–3.
 4. Ahn CH, Choi J-W, Beaucage G, Nevin JH, Lee J-B, Puntambekar A, Lee JY. 
Disposable smart lab on a chip for point-of-care clinical diagnostics. Proc 
IEEE. 2004;92:154–73.
 5. Chin CD, Linder V, Sia SK. Commercialization of microfluidic point-of-care 
diagnostic devices. Lab Chip. 2012;12:2118–34.
 6. Sista R, Hua Z, Thwar P, Sudarsan A, Srinivasan V, Eckhardt A, Pollack M, 
Pamula V. Development of a digital microfluidic platform for point of care 
testing. Lab Chip. 2008;8:2091–104.
 7. Sorger PK. Microfluidics closes in on point-of-care assays. Nat Biotechnol. 
2008;26:1345–6.
 8. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and valida-
tion: the long and uncertain path to clinical utility. Nat Biotechnol. 
2006;24:971–83.
 9. Rusling JF, Kumar CV, Gutkind JS, Patel V. Measurement of biomarker pro-
teins for point-of-care early detection and monitoring of cancer. Analyst. 
2010;135:2496–511.
 10. Boja ES, Jortani SA, Ritchie J, Hoofnagle AN, Težak Ž, Mansfield E, Keller P, 
Rivers RC, Rahbar A, Anderson NL. The journey to regulation of protein-
based multiplex quantitative assays. Clin Chem. 2011;57:560–7.
 11. Fu Q, Schoenhoff FS, Savage WJ, Zhang P, Van Eyk JE. Multiplex assays for 
biomarker research and clinical application: translational science coming 
of age. PROTEOMICS Clin Appl. 2010;4:271–84.
 12. Fu Q, Zhu J, Van Eyk JE. Comparison of multiplex immunoassay platforms. 
Clin Chem. 2010;56:314–8.
 13. Volpetti F, Garcia-Cordero J, Maerkl SJ. A microfluidic platform for 
high-throughput multiplexed protein quantitation. PLoS One. 
2015;10:e0117744.
 14. Mitchell P. Microfluidics-downsizing large-scale biology. Nat Biotechnol. 
2001;19:717–21.
 15. Sierra-Rodero M, Fernández-Romero JM, Gómez-Hens A. Strategies to 
improve the analytical features of microfluidic methods using nanomate-
rials. TrAC Trends Anal Chem. 2014;57:23–33.
 16. Choi J-W, Oh KW, Thomas JH, Heineman WR, Halsall HB, Nevin JH, 
Helmicki AJ, Henderson HT, Ahn CH. An integrated microfluidic biochem-
ical detection system for protein analysis with magnetic bead-based 
sampling capabilities. Lab Chip. 2002;2:27–30.
 17. Sista RS, Eckhardt AE, Srinivasan V, Pollack MG, Palanki S, Pamula VK. 
Heterogeneous immunoassays using magnetic beads on a digital micro-
fluidic platform. Lab Chip. 2008;8:2188–96.
 18. Lim C, Zhang Y. Bead-based microfluidic immunoassays: the next genera-
tion. Biosens Bioelectron. 2007;22:1197–204.
 19. Medina-Sánchez M, Miserere S, Merkoçi A. Nanomaterials and lab-on-a-
chip technologies. Lab Chip. 2012;12:1932–43.
 20. Pumera M, Escarpa A. Nanomaterials as electrochemical detectors in 
microfluidics and CE: fundamentals, designs, and applications. Electro-
phoresis. 2009;30:3315–23.
 21. Leamon JH. Multiplexed microfluidic immunoassays; 2014.
 22. Chowdhury F, Williams A, Johnson P. Validation and comparison of two 
multiplex technologies, Luminex® and mesoscale discovery, for human 
cytokine profiling. J Immunol Methods. 2009;340:55–64.
 23. Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW. Glycoproteomics for 
prostate cancer detection: changes in serum PSA glycosylation patterns. J 
Proteome Res. 2008;8:613–9.
 24. Li D, Chiu H, Chen J, Zhang H, Chan DW. Integrated analyses of proteins 
and their glycans in a magnetic bead-based multiplex assay format. Clin 
Chem. 2013;59:315–24.
 25. Li D, Chiu H, Gupta V, Chan DW. Validation of a multiplex immunoas-
say for serum angiogenic factors as biomarkers for aggressive prostate 
cancer. Clin Chim Acta. 2012;413:1506–11.
 26. Cao W, Chen L, Fu Y, Tan Z, Qu B. A highly efficient and versatile microchip 
capillary electrophoresis method for DNA separation using gold nano-
particle as a tag. J Sep Sci. 2011;34:939–46.
 27. Ko YJ, Maeng JH, Ahn Y, Hwang SY, Cho NG, Lee SH. Microchip-based 
multiplex electro-immunosensing system for the detection of cancer 
biomarkers. Electrophoresis. 2008;29:3466–76.
 28. Mirasoli M, Guardigli M, Michelini E, Roda A. Recent advancements in 
chemical luminescence-based lab-on-chip and microfluidic platforms for 
bioanalysis. J Pharm Biomed Anal. 2014;87:36–52.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
